NCT02282917 2025-12-05
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
Phase EARLY_PHASE1 Terminated
Clinical Trials
10 trialsNCT03095248 2025-04-22
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Phase 2 Terminated
NCT04351373 2023-08-01
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Mayo Clinic
Phase 2 Completed
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT00863122 2021-01-12
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT02309099 2019-01-07
Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach
University of North Carolina, Chapel Hill
Phase NA Completed
NCT01207687 2018-08-27
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00973739 2016-03-22
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase 2 Completed
NCT00411216 2015-08-07
Recovery of Visual Acuity in People With Vestibular Deficits
Emory University
Phase NA Completed